| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
139,126,000 |
| Market
Cap: |
128.39(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.9052 - $5.03 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile bluebird bio is a company focused on the pursuit of curative gene therapies for severe genetic diseases. Co. has late-stage clinical and research programs for the treatment of sickle cell disease (SCD), ss-thalassemia and cerebral adrenoleukodystrophy and is developing research to apply new technologies to these and other diseases. Using a proprietary lentiviral vector platform, Co. custom designs each of its therapies to address the underlying cause of disease by introducing a functional copy of a gene to patients' own isolated hematopoietic stem cells. Co. is developing lovotibeglogene autotemcel as a one-time treatment for patients with SCD.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
27,248 |
35,533 |
57,514 |
116,582 |
| Total Sell Value |
$35,492 |
$61,294 |
$139,194 |
$443,003 |
| Total People Sold |
4 |
5 |
5 |
9 |
| Total Sell Transactions |
6 |
9 |
12 |
23 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Colvin Richard A |
Chief Medical Officer |
• – – |
2022-11-04 |
4 |
S |
$6.41 |
$1,398 |
D/D |
(218) |
74,788 |
|
27% |
|
| Colvin Richard A |
Chief Medical Officer |
• – – |
2022-11-01 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
75,006 |
|
- |
|
| Leiderman Elisabeth |
|
– • – |
2022-10-17 |
4 |
S |
$6.46 |
$6,490 |
D/D |
(1,004) |
11,466 |
|
24% |
|
| Klima Thomas J |
See Remarks |
• – – |
2022-09-01 |
4 |
A |
$0.00 |
$0 |
D/D |
11,000 |
82,439 |
|
- |
|
| Colvin Richard A |
Chief Medical Officer |
• – – |
2022-08-22 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
45,006 |
|
17% |
|
| Cole Jason |
Chief Strategy & Financial Off |
• – – |
2022-08-19 |
4 |
S |
$5.53 |
$78,473 |
D/D |
(14,194) |
189,546 |
|
-16% |
|
| Cole Jason |
Chief Strategy & Financial Off |
• – – |
2022-08-04 |
4 |
S |
$4.39 |
$32,707 |
D/D |
(7,448) |
203,740 |
|
-70% |
|
| Obenshain Andrew |
President and CEO |
• • – |
2022-08-04 |
4 |
S |
$4.39 |
$95,754 |
D/D |
(21,805) |
247,131 |
|
-70% |
|
| Eggimann Anne-Virginie |
Chief Regulatory Officer |
• – – |
2022-07-12 |
4 |
S |
$4.95 |
$6,722 |
D/D |
(1,358) |
42,252 |
|
-35% |
|
| Leschly Nick |
|
– • – |
2022-06-22 |
4 |
A |
$0.00 |
$0 |
D/D |
3,109 |
284,439 |
|
- |
|
| Tita-Reid Najoh |
|
– • – |
2022-06-22 |
4 |
A |
$0.00 |
$0 |
D/D |
3,109 |
12,470 |
|
- |
|
| Agwunobi John O |
|
– • – |
2022-06-22 |
4 |
A |
$0.00 |
$0 |
D/D |
3,109 |
15,674 |
|
- |
|
| Vachon Mark |
|
– • – |
2022-06-22 |
4 |
A |
$0.00 |
$0 |
D/D |
4,353 |
14,251 |
|
- |
|
| Jones-Burton Charlotte |
|
– • – |
2022-06-22 |
4 |
A |
$0.00 |
$0 |
D/D |
3,109 |
7,772 |
|
- |
|
| Leiderman Elisabeth |
|
– • – |
2022-06-22 |
4 |
A |
$0.00 |
$0 |
D/D |
3,109 |
12,470 |
|
- |
|
| Klima Thomas J |
Chief Commercial Officer |
• – – |
2022-06-03 |
4 |
S |
$3.07 |
$11,535 |
D/D |
(3,753) |
71,439 |
|
-116% |
|
| Jones-Burton Charlotte |
|
– • – |
2022-03-07 |
4 |
A |
$0.00 |
$0 |
D/D |
4,663 |
4,663 |
|
- |
|
| Cole Jason |
Chief Business Officer |
• – – |
2022-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
211,188 |
|
- |
|
| Consylman Gina |
Chief Financial Officer |
• – – |
2022-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
125,385 |
|
- |
|
| Whitten Jessica |
Chief Accounting Officer |
• – – |
2022-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
7,500 |
56,913 |
|
- |
|
| Obenshain Andrew |
President and CEO |
• • – |
2022-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
18,000 |
268,936 |
|
- |
|
| Eggimann Anne-Virginie |
Chief Regulatory Officer |
• – – |
2022-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
17,000 |
43,610 |
|
- |
|
| Klima Thomas J |
Chief Commercial Officer |
• – – |
2022-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
75,192 |
|
- |
|
| Eggimann Anne-Virginie |
Chief Regulatory Officer |
• – – |
2022-01-11 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
26,610 |
|
-66% |
|
| Leschly Nick |
|
– • – |
2022-01-11 |
4 |
S |
$9.64 |
$48,869 |
D/D |
(5,068) |
281,330 |
|
66% |
|
939 Records found
|
|
Page 2 of 38 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.01 (1.13%) 
